Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Pyridoxine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.83 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.83 |
| ▸ | HPGD | P15428 | 4/20 | 0.83 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.83 |
| ▸ | LMNA | P02545 | 4/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.54 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.53 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.53 |
| ▸ | PDXK | O00764 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 3/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | CA9 | Q16790 | 3/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyridoxine SCHEMBL23647341 | 1.00 | KDM4E (0.83) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| Pyridoxine SCHEMBL15486045 | 0.98 | KDM4E (0.80) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| Pyridoxine SCHEMBL9168156 | 0.98 | KDM4E (0.80) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| Pyridoxine SCHEMBL5346680 | 0.92 | KDM4E (0.80) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| Pyridoxine SCHEMBL30267871 | 0.91 | HPGD (1.00) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| Pyridoxine SCHEMBL2322958 | 0.91 | HPGD (1.00) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| Pyridoxine SCHEMBL30877002 | 0.91 | HPGD (1.00) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| Pyridoxine SCHEMBL3506 | 0.91 | HPGD (1.00) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| Pyridoxine SCHEMBL31514964 | 0.90 | KDM4E (0.77) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| Pyridoxine SCHEMBL4576970 | 0.90 | KDM4E (0.77) | KDM4EALDH1A1HPGDHSD17B10LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144747-A1 | SYRUP PREPARATION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2026-05-28 | — | — | US | disclosed |
| EP-3871655-B1 | COMPOSITION FOR ORAL CAVITY | SUNSTAR INC (JP) | 2026-05-20 | — | — | EP | disclosed |
| US-12564594-B2 | Pharmaceutical composition containing 9-ethyl-6, 6-dimethyl-8-(4-morpholin-4-yl-piperidin-1-yl)-11-oxo-6, 11-dihydro-5H-benzo[b]carbazole-3-carbonitrile | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2026-03-03 | — | — | US | disclosed |
| EP-4606435-A2 | PHARMACEUTICAL COMPOSITION COMPRISING POORLY SOLUBLE BASIC AGENT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-08-27 | — | — | EP | disclosed |
| EP-4316598-B1 | PHARMACEUTICAL COMPOSITION COMPRISING A POORLY SOLUBLE BASIC AGENT | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2025-06-18 | — | — | EP | disclosed |
| WO-2025052869-A1 | EXTERNAL-USE COMPOSITION AND METHOD FOR ENHANCING FRAGRANCE OF SAME | ロート製薬株式会社 | 2025-03-13 | — | — | WO | disclosed |
| WO-2025053092-A1 | CLEANSING COMPOSITION AND METHOD FOR REMOVING AGING ODOR | ロート製薬株式会社 | 2025-03-13 | — | — | WO | disclosed |
| WO-2024219410-A1 | SKIN PERMEATION PROMOTER FOR HYALURONIC ACID, SKIN PERMEATION PROMOTION METHOD FOR HYALURONIC ACID, SKIN PERMEATION INHIBITOR FOR HYALURONIC ACID, AND SKIN PERMEATION INHIBITION METHOD FOR HYALURONIC ACID | ロート製薬株式会社 | 2024-10-24 | — | — | WO | disclosed |
| EP-4424313-A1 | SYRUP PREPARATION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-09-04 | — | — | EP | disclosed |
| CN-112384223-B | Pharmaceutical composition containing poorly soluble basic agent | 中外制药株式会社 | 2024-08-27 | — | — | CN | disclosed |
| EP-2412367-A1 | SOLID PREPARATION | Lintec Corporation (JP) | 2012-02-01 | — | — | EP | disclosed |
| EP-2412366-A1 | SOLID PREPARATION | LINTEC Corporation (JP) | 2012-02-01 | — | — | EP | disclosed |
| US-20120021059-A1 | SOLID PREPARATION | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2012-01-26 | — | — | US | disclosed |
| US-20110027326-A1 | External Composition for Skin | ROHTO PHARMACEUTICAL CO., LTD. (JP) | 2011-02-03 | — | — | US | disclosed |
| EP-2269652-A1 | COMPOSITION FOR EXTERNAL APPLICATION TO SKIN | Rohto Pharmaceutical Co., Ltd. (JP) | 2011-01-05 | — | — | EP | disclosed |
| US-20100209364-A1 | Emulsified Composition | ROHTO PHARMACEUTICAL CO., LTD. (JP) | 2010-08-19 | — | — | US | disclosed |
| US-20100021405-A1 | EXTERNAL PREPARATION FOR SKIN | ROHTO PHARMACEUTICAL CO., LTD. (JP) | 2010-01-28 | — | — | US | disclosed |
| US-20080207560-A1 | Composition For External Use | ROHTO PHARMACEUTICAL CO., LTD. (JP) | 2008-08-28 | — | — | US | disclosed |
| EP-1849481-A1 | COMPOSITION FOR EXTERNAL USE | ROHTO PHARMACEUTICAL CO., LTD. (JP) | 2007-10-31 | — | — | EP | disclosed |
| US-20020099032-A1 | Preparations and method of producing the same | ROHTO PHARMACEUTICAL CO., LTD. (JP) | 2002-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12564594-B2 | Pharmaceutical composition containing 9-ethyl-6, 6-dimethyl-8-(4-morpholin-4-yl-piperidin-1-yl)-11-oxo-6, 11-dihydro-5H-benzo[b]carbazole-3-carbonitrile | KCNN2, KCNN1, KIT | KDM4E 971/4885ALDH1A1 4665/4885HPGD 2808/4885 |
| US-20260144747-A1 | SYRUP PREPARATION | ALK, IRAK1, IRAK3 | KDM4E 2195/4885ALDH1A1 1620/4885HPGD 4611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.